![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 53, 37525-37532, December 31, 1999
§
From the
Department of Adult Oncology, Dana-Farber
Cancer Institute, and the Departments of Medicine, Brigham and Women's
Hospital and Harvard Medical School, Boston, Massachusetts 02115
| |
ABSTRACT |
|---|
|
|
|---|
Crkl, an SH2-SH3-SH3 adapter protein, is one of
the major tyrosine phosphoproteins detected in cells from patients with
chronic myelogenous leukemia. Crkl binds to BCR/ABL through its
N-terminal SH3 domain and is known to interact with several signaling
proteins that have been implicated in integrin signaling, including
Cbl, Cas, Hef-1, and paxillin. We have previously shown that
overexpression of Crkl enhances adhesion to extracellular matrix
proteins through Crkl is a 39-kDa adapter protein containing one SH2 and two SH3
domains. The Crkl gene was originally identified by ten Hoeve et
al. (1) and found to have an overall amino acid homology of 60%
to Crkii, one of two proteins generated through alternative splicing of
the human Crk proto-oncogene. Both Crkl and Crk are related to
v-Crk, the oncogene in the avian retrovirus CT10. Crkl has
been shown to be involved in a number of signaling pathways, including
pathways activated by T cell stimulation, integrin cross-linking, and
hematopoietic cytokine receptor activation (2-8). Also, we and others
have shown that Crkl is a target of the BCR/ABL oncogene in chronic
myelogenous leukemia cells (9-17). Although the function of Crkl
remains unknown, several investigators have shown that Crkl interacts
with signaling proteins previously linked to the control of
cytoskeletal functions. In particular, both the Crkl and Crk SH3
domains bind to an overlapping set of cellular target proteins in
vitro, including c-ABL, C3G, EPS15, DOCK180, and SOS, and the Crkl
and Crk SH2 domains also share in vitro binding to c-Cbl,
Cas, Hef-1, and paxillin (18-24, 26-28). Overexpression of Crkl in
hematopoietic cells enhances integrin-mediated cell adhesion to
fibronectin-coated surfaces (2, 29). These observations led us to
examine the role of Crkl in cell migration, an event that requires
coordination of cellular polarization, membrane extension, formation of
cell-substratum attachments, contractile force, traction, and release
of rear attachment sites. Although cell adhesion to the substratum is
required for migration it is not sufficient, and it is likely that
important signals regulating migration come from many different sources
including integrins, cytokine receptors, chemokine receptors, and
others. The results indicate that Crkl is involved in the regulation of
migration, likely involving an interaction with the guanine nucleotide
exchange factor, C3G.
Plasmids--
A human Crkl cDNA was obtained from Dr. John
Groffen (Children's Hospital, Los Angeles, CA). In-frame deletions of
amino acids 14-64, 131-179, 238-290, and 131-290, respectively,
were made by polymerase chain reactions to create an SH2-, an
N-terminal SH3-, a C-terminal SH3-, and both SH3-domain(s) deletion
mutants (hereafter termed Crkl Transient Transfection of Ba/F3 Cells--
The murine
hematopoietic cell line, Ba/F3, was cultured in RPMI 1640 containing
10% fetal calf serum and 15% WEHI3B cell conditioned medium as a
source of murine interleukin-3. Ba/F3 cells were transfected with
plasmids by electroporation using a Gene Pulser apparatus (Bio-Rad).
For migration assays GFP-expressing cells were purified by
fluorescence-activated cell sorting 18 h after transfection using
an EPICS Elite-EPS cytometer (Coulter Corp., Hialeah, FL).
Migration Assays--
Migration assays were performed using
Transwell plates (0.33 cm2 insert growth area, 8 µm
pores; Corning Coster Corp. Cambridge, MA). Both sides of the porous
polycarbonate membrane were coated with human fibronectin (5 µg/ml).
The lower chamber contained 600 µl of RPMI 1640 medium containing 1%
bovine serum albumin (BSA). Fluorescence-activated cell sorting
(FACS)-purified cells were starved in RPMI 1640 containing 1% BSA for
6 h, placed into the upper chamber (1 × 105
cells/100 µl of RPMI 1640 containing 1% BSA), and allowed to migrate
into the lower chamber for 6-8 h. In some experiments, recombinant
human SDF-1 Integrin Cross-linking--
18 h after transfection cells were
removed from interleukin-3 containing medium and placed in RPMI 1640 containing 1% BSA for 6 h. To induce integrin signaling, cells
were suspended in phosphate-buffered saline (1 × 107/ml), incubated for 10 min on ice with antibody against
murine Immunoblotting and Immunoprecipitation--
Cells were lysed in
buffer containing 50 mM Tris (pH 8.0), 150 mM
NaCl, 10% glycerol, 1% Nonidet P-40, 10 mM EDTA, 100 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin, 1 mM sodium orthovanadate, and 40 mg/ml
leupeptin. Immunoprecipitation and immunoblotting were performed as
described previously (17). For immunodepletion studies, cell lysates
were incubated with either anti-Cbl antibody or preimmune rabbit serum
with protein A-Sepharose, and the resulting supernatants were used for immunoprecipitation.
Other antibodies used in this study were anti-Crkl monoclonal
antibodies (#5-6 and #2-2), anti-Crkl polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-phosphotyrosine monoclonal antibody (4G10; provided by Dr. Brian J. Druker, Oregon Health Science
University, Portland, OR), anti-Cbl polyclonal antibody (Santa Cruz
Biotechnology), anti-Cas monoclonal antibody (Transduction Laboratories, Lexington, KY), anti-C3G polyclonal antibody (Santa Cruz
Biotechnology), anti-ABL monoclonal antibody (Ab-3; Oncogene Science,
Manhasset, NY), anti-DOCK180 polyclonal antibody (Santa Cruz
Biotechnology), and anti-GFP polyclonal antibody
(CLONTECH).
Overexpression of Crkl and Crk, but Not Grb2, Increases Random Cell
Migration on Fibronectin-coated Surfaces--
The hematopoieticU cell
line Ba/F3 was selected for these studies because it is capable of
migration on two-dimensional surfaces and across three-dimensional
membranes, and because it expresses appropriate receptors for
extracellular matrix proteins, hematopoietic growth factors, and
chemokines such as SDF-1
Migration of GFP-Crkl-overexpressing cells was significantly increased
(2.8-fold) compared with GFP-expressing cells (Fig. 1A). Overexpression of GFP
alone had no significant effect on migration compared with
untransfected cells or sham transfected cells (data not shown). To
ensure that the observed effects were because of Crkl and unique to the
fusion protein, Crkl and GFP were individually expressed in the same
cells from different vectors, and migration experiments were repeated.
Again, Crkl overexpression enhanced spontaneous migration, suggesting
that the presence of the GFP tag did not alter Crkl function in this
assay (data not shown). The Crkl-related adapter protein, Crkii, also
increased migration but was reproducibly less effective than Crkl in
these hematopoietic cells. The enhanced migration was likely to involve Both SH2 and N-terminal SH3 Domains of Crkl Are Necessary to
Increase Migration--
Overexpression of full-length Crkl was
compared with deletion mutants in which the SH2 or SH3 domains had been
deleted (Fig. 1, A and C). In contrast to
full-length Crkl, overexpression of GFP-Crkl SDF-1 Identification of Cbl as the Major Crkl-SH2-binding Protein after
The pp120 protein(s) coprecipitating with Crkl was found to be composed
predominantly of Cbl (Fig. 3). Cbl
coprecipitated with GFP-Crkl after the cross-linking of
In Crkl-overexpressing cells, a small amount of Cbl coprecipitated with
Crkl even in resting, non-adherent, cells. This finding led us to
examine whether overexpression of Crkl prolongs tyrosine phosphorylation of Cbl by blocking access of phosphatases to
phosphotyrosine residues. Cbl was rapidly tyrosine-phosphorylated after
integrin ligation, followed by nearly complete dephosphorylation within 60 min in either mock or Crkl-transfected cells (Fig. 3D).
This result suggests that Crkl overexpression does not affect the
kinetics of tyrosine phosphorylation or dephosphorylation of Cbl after integrin ligation. The increased association of Cbl with Crkl in
resting, Crkl-overexpressing cells may be due to the fact that Cbl is
relatively abundant in the cell and that the formation of a Cbl-Crkl
complex is limited by the available Crkl. Interestingly, Crkl
Because Cbl was the major protein interacting with the Crkl
Some of the other tyrosine phosphoproteins that are coprecipitated with
Crkl after integrin cross-linking were identified. The protein at 140 kDa was identified as SHIP (33) (data not shown). The protein at 40 kDa
was tyrosine-phosphorylated Crkl (data not shown). In a longer
exposure, a 70-kDa protein detected in Crkl immune complexes after
integrin cross-linking in Crkl-overexpressing cells was identified as
the SH2 containing tyrosine phosphatase SHP-2 (34) (data not shown). It
is also possible that one or more of these proteins play a role in the
regulation of migration, and further studies are underway to address
this point.
C3G Cooperates with Crkl to Increase Cell Migration--
Because
overexpression of Crkl enhanced migration and overexpression of
Crkl
To examine the role of some of these proteins, we overexpressed C3G,
c-ABL, or DOCK180 and determined if they cooperated with Crkl to
increase cell migration. As expected, overexpression of C3G, c-ABL, or
DOCK180 with Crkl led to the detection of increased complexes of Crkl
with C3G, ABL, or DOCK180, respectively (Fig. 4A). Cotransfection of C3G and
GFP-Crkl further increased cell migration significantly as compared
with transfection of GFP-Crkl alone, whereas cotransfection of c-ABL or
DOCK180 did not have any further effect on migration of
Crkl-overexpressing cells (Fig. 4B). Interestingly,
overexpression of C3G alone did not have any significant effects on
cell migration. However, C3G cooperated with Crkl to enhance cell
migration (Fig. 4C). These results indicate that the
Crkl-C3G complex may play an important role in increasing cell
migration and that Crkl, but not C3G, is rate-limiting for this
effect.
The association of C3G with Crkl in cells overexpressing deletion
mutants of Crkl was also examined. Overexpression of wild type Crkl,
Crkl Cell migration is a fundamentally important process that is not
well understood at the level of signal transduction. During development, many precursor cells migrate in response to specific stimuli such as a gradient of chemoattractant molecules. In addition, numerous cells of the adult organism are also capable of extensive migration, particularly cells involved in wound healing and those of
the hematopoietic and immune systems. Migration involves a carefully
orchestrated series of events that allows cells to extend a cellular
protrusion, attach to extracellular matrix proteins through integrins
or other adhesive molecules, move in the direction of attachment, and
simultaneously detach at the trailing edge (42). Whereas much is known
about the events regulating changes in actin structure during cell
movement, little is known about the signals from integrins or other
receptors that initiate migration.
Members of the Crk family have previously been shown to participate in
signaling pathways activated by integrins and have been further linked
to the control of adhesion and migration (2, 18, 29, 30, 41,
43).1 For example, after integrin cross-linking in
hematopoietic cells, Crkl is rapidly tyrosine-phosphorylated and binds
through its SH2 domain to other cellular tyrosine phosphoproteins (29). The SH3 domains of Crk and Crkl bind constitutively to an overlapping set of cellular proteins that have also been linked in some cases to
integrin signaling, including c-ABL, DOCK180, and C3G (17). Overexpression of either Crkii or Crkl has been shown to increase short-term integrin-mediated adhesion of 32D and Ba/F3 hematopoietic cells to fibronectin-coated surfaces (2, 29). Crkii, but not Crkl, has
also been linked to migration (44). Klemke et al. (44)
showed that Crkii-Cas complexes correlated with enhanced migration of
the FG-M carcinoma cell line and that dominant-negative mutants of
either CrkII or Cas inhibited spontaneous migration of this cell line.
Thus, it is likely that both Crkl and CrkII participate in signal
transduction initiated by The goal of the current studies was to develop a model system in which
the effects of specific signaling proteins activated by
The results presented here suggest that Crkl plays a similar role in
Ba/F3 cells to that of Crkii in epithelial carcinoma cells (44). As
shown here, overexpression of Crkii in Ba/F3 cells also enhanced
migration, but to a substantially less degree than did Crkl. These
results suggest that Crkl may be more significantly involved in
integrin signaling and migration in hematopoietic cells, whereas Crkii
is more important in non-hematopoietic cells. Interestingly,
overexpression of Crkl, but not Crkii, has been reported to transform
fibroblasts (45, 46). Overall, our results significantly extend the
understanding of the functions of Crkl and provide additional evidence
that Crkl is involved in signaling pathways that involve integrins.
Potential mechanisms to explain the migration-enhancing effects of Crkl
were explored by identifying the major cellular proteins that associate
with the Crkl Cbl has also been associated with integrin signaling and the
cytoskeleton. Cbl is prominently tyrosine-phosphorylated after integrin-mediated adhesion in many cell types (27, 52). It is localized
to the cytoplasm and has been shown to interact directly with several
cytoskeletal proteins, although the significance of these interactions
is unclear (53). Oncogenic forms of Cbl abrogate anchorage dependence
of fibroblasts for proliferation (52). After integrin ligation, Cbl
forms complexes with other proteins involved in cytoskeletal functional
regulation, including Src and PI3K (54). However, the role of Cbl in
regulating migration is unclear. In our study, overexpression of Cbl in
Ba/F3 cells did alter short-term adhesion or spontaneous migration,
although Cbl is already a relatively abundant protein in these cells.
The association and activation of PI3K by Cbl may provide a pathway that links Crkl to adhesion and migration, and further studies are
warranted to explore this possibility.
A second well known target of the Crkl SH2 domain is Cas, which is
likely to be involved in integrin signaling and regulation in some cell
types. Cas was discovered as a Crk-binding protein, and has multiple
YXXP motifs for binding Crk SH2 domains. Like Cbl, Cas
functions as a docking protein after integrin ligation, interacting
with 14-3-3 proteins (53, 55). In transient expression assays, Crk-Cas
complexes have been shown to activate c-Jun kinase through activation
of p21rac (56). In these cells, activation of
Rac was believed to occur through DOCK180, which was brought to Cas by
Crkii (41). Homologues of DOCK180 in both Drosophila
melanogaster (Myoblast City) and C. elegans (ced-5)
have also been linked to the formation of cell extensions, migration,
or both (57). Activation of Rac is frequently associated with enhanced
migration and adhesion and would explain the enhanced migration of
cells transiently overexpressing Crkl (41). However, DOCK180 is not
expressed at detectable levels in Ba/F3 and many other hematopoietic
cell lines, suggesting that either a related protein exists or that
there are other pathways involved. Of note, v-Crk does
not activate Rac in PC12 cells but does activate Rho, thereby
inducing cell spreading and focal adhesion formation (58).
Overexpression of another Crkl SH3-binding protein, C3G, did enhance
spontaneous migration but only when expressed with Crkl. C3G is a
guanine nucleotide exchange factor for the small G protein Rap1, also
known as smg p21 or Krev-1, originally identified as an anti-oncogenic
protein capable of reversing the morphologic transformation of
fibroblasts by v-Ki-Ras (59). Rap1 is likely to antagonize Ras by
competition with the effector domain. Binding of either Crk or Crkl SH3
domains to C3G has been shown to activate the guanine nucleotide
exchange activity of C3G (36), possibly by inducing translocation to
the membrane or other sites. The functions of C3G and Rap1 are
incompletely understood, but both have been associated with adhesion or
migration. C3G is tyrosine-phosphorylated after integrin stimulation in
normal cells (35). C3G can interact directly with Cas through the SH3
domain of Cas, in addition to an indirect interaction through Crk or
Crkl (60). Rap1 has been shown to be activated during cell adhesion,
and the basal Rap1 activity is cell density-dependent (32).
However, direct links between C3G, Rap1, and the regulation of adhesion
or migration have not been reported. The results presented here suggest
that additional studies on the role of C3G and Rap1 and integrin
signaling, adhesion, and migration are warranted.
Overall, the present report suggests that Crkl plays a prominent role
in mediating integrin-mediated signals in hematopoietic cells and
further suggest that the functions of Crkl and Crkii are, at least in
part, distinct. In non-hematopoietic cells, integrin-induced formation
of Cas-Crk complexes activates migration, possibly through bringing
DOCK180 to the cytoskeleton or membrane (44). In hematopoietic cells,
Cbl-Crkl complexes predominate, but downstream signals are unclear. C3G
is proposed as one pathway that can induce migration through this
complex. Crkl is likely to link C3G to Cbl after integrin
cross-linking, because Cbl is the predominant target of the Crkl SH2
domain in hematopoietic cells. In cells transformed by tyrosine kinase
oncogenes such as p210BCR-ABL, Crkl and Cbl are constitutively
tyrosine-phosphorylated and form a permanent complex independent of
integrin activation (17, 25). This complex is likely to contribute to
the abnormal adhesion and migration exhibited by BCR/ABL transformed
hematopoietic cells.
1 integrins. In this study, the
effects of Crkl on spontaneous and chemokine-directed migration of the
hematopoietic cell line Ba/F3 were examined. Full-length, SH2-, and
SH3(N)-domain deletion mutants of Crkl were expressed transiently as
fusion proteins with green fluorescent protein. Successfully
transfected cells were isolated by fluorescence-activated cell sorting.
The ability of these cells to migrate across a fibronectin-coated
membrane, either spontaneously or in response to the chemokine
stromal-derived factor-1
, was determined. Cells expressing green
fluorescent protein alone were not distinguishable from untransfected
or mock transfected Ba/F3 cells. However, Ba/F3 cells overexpressing
full-length Crkl were found to have an increase in spontaneous
migration of 2.8 ± 0.6-fold in seven independent assays. The
enhancement of migration required both the SH2 domain and the
N-terminal SH3 domain. Migration in response to stromal-derived
factor-1
was not significantly enhanced by overexpression of Crkl.
Overexpression of Crkii also augmented spontaneous migration but to a
lesser degree than did Crkl. Because the SH2 domain was required for enhanced migration, we looked for changes in phosphotyrosine containing proteins coprecipitating with Crkl, but not Crkl
SH2, after integrin cross-linking. Full-length Crkl, but not Crkl
SH2, coprecipitated with a single major tyrosine phosphoprotein with an
Mr of approximately 120 kDa, identified as Cbl.
The major Crkl SH3-binding protein in these cells was found to be the
guanine nucleotide exchange factor, C3G. Interestingly, overexpression
of C3G also enhanced migration, suggesting that a Cbl-Crkl-C3G complex
may be involved in migration signaling in Ba/F3 cells. These data
suggest that Crkl is involved in signaling pathways that regulate
migration, possibly through a complex with Cbl and C3G.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
SH2, Crkl
SH3(N), Crkl
SH3(C), and
Crkl
SH3(N+C), respectively) (29). Crkl and Crkl deletion
mutants were cloned into mammalian expression vectors, pEBB and pEGFP-C
(CLONTECH, Palo Alto, CA), resulting in the
expression of green fluorescent protein
(GFP)1-Crkl fusion proteins.
A human Grb2 cDNA was obtained from Dr. Akio Yamakawa (Dana-Farber
Cancer Institute), and was also cloned in frame in the pEGFP-C vector.
A murine c-ABL cDNA was obtained from Dr. Richard A. Van Etten
(Center for Blood Research, Harvard Medical School, Boston, MA). A
human C3G cDNA and a human DOCK180 cDNA were obtained from Dr.
Michiyuki Matsuda (International Medical Center of Japan, Tokyo, Japan)
and cloned into the pEBB vector. A hemagglutinin-tagged human Cbl
cDNA in the pALTER-MAX expression vector was obtained from Dr.
Hamid Band (Harvard Medical School).
(R & D Systems, Minneapolis, MN) (31) was added to the
lower chamber.
1 integrin (Ha2/5, PharMingen, San Diego, CA) or
hamster IgM as a control, washed in phosphate-buffered saline, and
stimulated by cross-linking using anti-hamster IgM at 37 °C for 5 min.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
(the CXCR4
receptor).2 Migration assays
were performed using modified Boyden chambers (Transwell membranes)
coated with fibronectin on both surfaces. Crkl, mutants of Crkl, Crk,
Grb2, or other test genes were expressed transiently along with
appropriate controls in all cell migration experiments. To obtain cell
populations in which the transgenes were overexpressed in more than
90% of cells, plasmids encoding GFP fusion proteins
were transfected by electroporation, and positive cells were isolated
by FACS. The protein expression of GFP fusion proteins was confirmed by
immunoblotting using specific antibodies and an anti-GFP antibody. This
technique had the advantage of allowing for purification of cell
populations that expressed approximately equivalent amounts of each
transgene, because cells were isolated that expressed approximately
equivalent amounts of fluorescence by FACS.
1 integrins, because there was no significant migration
if the Transwell membranes were not coated with fibronectin (data not shown). Also, the effects of Crkl on Transwell migration were not a
general property of adapter proteins, because overexpression of Grb2
did not have any significant effects on cell migration in this system
(Fig. 1B).

View larger version (10K):
[in a new window]
Fig. 1.
Crkl enhances cell migration.
A, Ba/F3 cells were transfected with pEGFP-C, pEGFP-C-Crkl,
or pEGFP-C-Crkl
SH2. After 18 h, GFP-expressing cells were
enriched to >90% fluorescence by FACS and then used for random
migration assays as described under "Materials and Methods." The
vertical axis shows relative migration expressed as the ratio of the
number of GFP-Crkl transfected cells migrating to the number of
GFP/control transfected cells migrating over the same time period.
Shown is the mean ± S.D. of seven inde- pendent experiments; each experiment was performed using
triplicate wells. B, Ba/F3 cells were transfected with
pEGFP-C, pEGFP-C-Crkl, or pEGFP-C-Grb2, and the migration index was
calculated as above. Shown is the mean ± S.D. of three
independent experiments. C, Ba/F3 cells were transfected
with pEGFP-C, pEGFP-C-Crkl (FL, full-length Crkl),
pEGFP-C-Crkl
SH3(N), pEGFP-C-Crkl
SH3(C), or
pEGFP-C-Crkl
SH3(N+C), and the migration index was calculated. Shown
is the mean ± S.D. of three independent experiments.
SH2 did not alter cell
migration, and overexpression of GFP-Crkl
SH3(N) significantly
inhibited migration of Ba/F3 cells (Fig. 1C). Overexpression
of GFP-Crkl
SH3(C) increased migration, although to a lesser degree
than that of GFP-Crkl. Overexpression of GFP-Crkl
SH3(N+C) reduced
migration. These results indicate that the SH2 and the N-terminal, but
not the C-terminal, SH3 domains are required to enhance random
migration of Ba/F3 cells. Further, because overexpression of
GFP-Crkl
SH3(N) inhibited migration below the base-line value
exhibited by control cells, this mutant may function as
dominant-negative in a pathway required for regulating migration.
Overrides the Modulation of Migration by Overexpression of
Crkl--
The above findings support the hypothesis that Crkl may play
an important role in overall random migration of hematopoietic cells on
fibronectin-coated surfaces. This raised the question whether
overexpression of Crkl also affects cell migration induced by
chemoattractant gradients. We have previously shown that Ba/F3 cells
express the receptor for SDF-1
, CXCR4, and migrate avidly along an
SDF-1
gradient in vitro and in
vivo.3 The effect of
overexpression of Crkl on SDF-1
-directed cell migration was
evaluated. Adding SDF-1
into the lower chamber increased migration
of all transfected cells tested. Overexpression of GFP-Crkl or
GFP-Crkl
SH3(N) did not alter migration of transfected Ba/F3 cells in
response to SDF-1
(data not shown).
1-integrin Ligation--
The above results suggest that
Crkl is likely to enhance spontaneous migration by linking to other
proteins using its SH2 domain and the N-terminal SH3 domain. To look
for proteins interacting with the Crkl-SH2 domain,
1
integrins were cross-linked using an anti-
1 integrin
antibody, and cell lysates were subjected to anti-Crkl
immunoprecipitation followed by immunoblotting with the
anti-phosphotyrosine monoclonal antibody 4G10 (Fig.
2). Cross-linking
integrins in mock
transfected cells resulted in a substantial increase in the
coprecipitation of a 120-kDa phosphoprotein with Crkl. After
overexpression of wild type Crkl, the association of Crkl with pp120
was increased before integrin activation. Several other proteins were
detected in Crkl-overexpressing cells that were not observed in mock
transfected cells, including bands at approximately 140, 95, 60, and 40 kDa. The interaction of each of these proteins with Crkl, and the
enhanced binding to pp120, required the SH2 domain, because cells
overexpressing Crkl
SH2 were indistinguishable from mock transfected
cells (Fig. 2).

View larger version (31K):
[in a new window]
Fig. 2.
1-integrin
cross-linking induces tyrosine phosphorylation of Crkl and the
formation of tyrosine phosphoprotein complexes containing Crkl.
Ba/F3 cells were transfected with pEBB (mock), pEBB-Crkl, or
pEBB-Crkl
SH2. 18 h after transfection, cells were made
quiescent by culturing in RPMI 1640 medium with 1% bovine serum
albumin for 6 h and then stimulated by
1 integrin
cross-linking (+). Nonspecific immunoglobulin was used as a
control (-) as described under "Materials and Methods."
Cell lysates were used for immunoprecipitation with anti-Crkl
monoclonal antibody 5-6 and immunoblotted with anti-phosphotyrosine Ab
(4G10). Overexpression of the Crkl and Crkl
SH2 mutants
was confirmed by anti-Crkl blotting. The immunoglobulin heavy chain is
indicated as Ig.
integrins
(Fig. 3A). This was not affected by mutation of tyrosine 207 to phenylalanine, but Cbl did not coprecipitate with GFP-Crkl
SH2,
consistent with this interaction being mediated by the SH2 domain of
Crkl (Fig. 3A). In contrast to the SH2 deletion, the
integrin-induced association of Cbl with Crkl was only slightly reduced
by deleting either SH3 domain (Fig. 3B). To determine
whether Cbl was the major 120-kDa phosphoprotein induced to
coprecipitate with Crkl after integrin ligation, immunodepletion using
an anti-Cbl antibody was performed. Cbl immunodepletion significantly
reduced the amount of pp120 coprecipitating with Crkl, suggesting that
the Cbl is the major component of this band (Fig. 3C). An
anti-Cas antibody was also used to determine whether Crkl
coprecipitated with Cas. However, coprecipitation of Cas with Crkl in
Crkl-overexpressing cells was at the lower limit of detection. Further,
in these cells, cross-linking of
integrins induced only marginal
tyrosine phosphorylation of Cas (data not shown). Thus, integrin
signaling in Ba/F3 cells induces Crkl-SH2 to bind primarily to Cbl.

View larger version (34K):
[in a new window]
Fig. 3.
CBL is the major Crkl binding tyrosine
phosphoprotein after
1-integrin
cross-linking. A, Ba/F3 cells were transfected with
pEGFP-Crkl, pEGFP-Crkl Y207F, or pEGFP-C-Crkl
SH2. Cell lysates from
cells transfected as shown were immunoprecipitated with anti-GFP Ab and
immunoblotted with anti-Cbl Ab or anti-Crkl Ab 5-6. Starvation and
1 integrin cross-linking were performed as described in
the legend for Fig. 1. B, Ba/F3 cells
were transfected with pEBB (mock), pEBB-Crkl
SH3(N), or
pEBB-CrklSH3(C). Cell lysates were immunoprecipitated with anti-Crkl Ab
5-6 and immunoblotted with anti-Cbl Ab. C, as in
B, cell lysates were first immunodepleted with anti-Cbl Ab
(+) or preimmune rabbit serum as a control (-)
and then anti-Crkl immunoprecipitation was performed, followed by
immunoblotting with phosphotyrosine (4G10) or anti-Cbl Ab as
shown. D, Ba/F3 cells transfected with either pEBB
(mock) or pEBB-Crkl were treated with anti-
1
integrin Ab (+) or nonspecific immunoglobulin
(-), washed, and then exposed to a secondary antibody for 5 or 60 min. Cell lysates were immunoprecipitated with anti-Cbl Ab and
immunoblotted with anti-phosphotyrosine Ab (4G10).
E, Ba/F3 cells were transfected with pEBB (mock)
or pEBB-Crkl
SH3(N). Cell lysates from transfected cells were
immunoprecipitated with anti-Crkl Ab 2-2, which recognizes only
endogenous Crkl because the epitope recognized by this antibody is in
the C-terminal SH3 domain, and immunoblotted with anti-Cbl Ab or
anti-Crkl Ab 5-6. Appropriate expression of Crkl
SH3(N) was
confirmed by immunoblotting of whole cell lysate with anti-Crkl Ab
5-6.
SH3(N)
competed with wild type endogenous Crkl for binding to phospho-Cbl
(Fig. 3E). Anti-Crkl monoclonal antibody 2-2, which recognizes an epitope in the N-terminal SH3 domain of Crkl, was used to
specifically detect binding of endogenous, full-length Crkl to Cbl.
Overexpression of Crkl
SH3(N) reduced the integrin-induced association of Cbl with endogenous Crkl as compared with mock transfected cells (Fig. 3E). One explanation for these
results is that both the level of Crkl and the level of Cbl tyrosine
phosphorylation are important to migration signaling. The ability of
Crkl
SH3(N) to compete with full-length Crkl for binding to
phospho-Cbl may contribute to the dominant-negative effects this Crkl
mutant had on spontaneous cell migration.
SH2
domain in Ba/F3 cells after integrin cross-linking, the effect of
overexpression of Cbl (approximately 3-fold) on cell migration was
examined. Overexpression of Cbl with either GFP or GFP-Crkl did not
have any additional significant effect on cell migration in multiple
experiments (data not shown). It is possible that Cbl is not involved
in regulating migration despite interacting directly with Crkl, that
the amount of endogenous Cbl is not rate-limiting for migration, or
that overexpressing Cbl does not increase the amount of phospho-Cbl
available for binding to Crkl.
SH3(N) inhibited migration, it is likely that one or more
Crkl
SH3 domain-binding proteins also contributes to the regulation
of migration in Ba/F3 cells. Several molecules have been reported to
bind to SH3 domains of Crk family proteins including c-ABL, SOS, C3G,
EPS15, and DOCK180 (19, 20, 28, 35-37). Among these molecules, several
have previously been linked to cytoskeletal regulation. The guanine
nucleotide exchange factor C3G has been found to be abundant in Crkl
complexes and is reported to play an important role in the signaling
through Crk family proteins (2, 18, 20, 27, 35, 36, 38). The kinase activity and localization of c-ABL have been reported to be regulated by integrin activation (39). DOCK180 has been found to regulate cytoskeletal function by cooperating with the Crk-Cas complex (40, 41).
However, DOCK180 is not expressed in hematopoietic cells, although a
homologue may be.

View larger version (17K):
[in a new window]
Fig. 4.
C3G cooperates with Crkl to increase cell
migration. A, Ba/F3 cells were co-transfected with
pEBB-Crkl (10 µg) and either pEBB (mock), pEBB-c-ABL,
pEBB-C3G, or pEBB-DOCK180 (20 µg each). Cell lysates were prepared
18 h after transfection and were immunoprecipitated with anti-Crkl
Ab 5-6 or preimmune mouse serum as a control and then immunoblotted
with anti-ABL Ab, anti-C3G Ab, or anti-DOCK180 Ab. Immunoprecipitation
and immunoblotting with anti-Crkl Ab (data not shown) detected a
comparable amount of Crkl in each transfection. B, the
migration ratio was determined in cells transfected with pEBB-Crkl and
cotransfected with mock, c-ABL, C3G, or DOCK180 vectors as indicated.
C, Ba/F3 cells were co-transfected with pEGFP-control or
pEGFP-C-Crkl (20 µg each) plus either pEBB or pEBB-C3G (20 µg
each). For B and C, GFP-expressing cells were
enriched to >90% purity by FACS 18 h after transfection,
cultured in serum- and growth factor-free medium for 6 h, and then
tested for migration as described above. Shown are results from two
independent experiments (mean ± S.D.). Each experiment was
performed using triplicate wells.
SH2, and Crkl
SH3(C), but not Crkl
SH3(N), led to increased
formation of Crkl-C3G complexes, consistent with the hypothesis that
C3G binds to Crkl through the N-terminal SH3 domain, further suggesting
that this complex is important in migration (Fig.
5A). Because we found that Cbl
was the most abundant Crkl-SH2-binding partner and that C3G was the
only SH3-binding partner of those tested that clearly altered
migration, we looked for evidence of complexes that might contain both
Cbl and C3G. After
1 integrin cross-linking, C3G was
detected in Cbl immunoprecipitates, and this was increased about 2-fold
in cells overexpressing wild type Crkl, further supporting the notion
that Crkl is the limiting factor in the formation of these complexes
(Fig. 5B).

View larger version (40K):
[in a new window]
Fig. 5.
C3G-Crkl complexes interact with Cbl
after
1 integrin
cross-linking. Ba/F3 cells were transfected with pEBB, pEBB-Crkl,
pEBB-Crkl
SH2, pEBB-Crkl
SH3(N), or pEBB-Crkl
SH3(C) as
indicated. Starvation and
1 integrin cross-linking were
performed as described above. A, lysates from transfected
cells were immunoprecipitated with anti-Crkl Ab 5-6 and immunoblotted
with anti-C3G Ab. B, lysates from transfected cells were
immunoprecipitated with anti-Cbl Ab and immunoblotted with anti-C3G Ab
or anti-Cbl Ab.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
integrins and, as adapter proteins, may
serve to link or transport critical signaling molecules that regulate
adhesion and possibly migration.
1 integrins could be studied in hematopoietic cells.
Compared with more commonly used fibroblastic or epithelial cell lines, hematopoietic cells display higher levels of motility and migration using in vitro assays. The Ba/F3 cell line was selected for
this study because its expression of integrin receptors and other
adhesion molecules is well characterized.2 Cross-linking of
1 integrins on Ba/F3 cells was found to cause rapid
tyrosine phosphorylation of Crkl and association of Crkl with other
tyrosine phosphoproteins, notably Cbl. Although Crkii is also expressed
at high levels in Ba/F3 cells, compared with Crkl, Crkii was only
minimally tyrosine-phosphorylated after integrin cross-linking and was
less involved in forming new protein-protein complexes. Transient
overexpression of intact Crkl enhanced spontaneous migration on
fibronectin-coated surfaces but not on uncoated surfaces. The role of
the SH2 and SH3 domains of Crkl were further explored by creating
specific deletion mutants and transiently overexpressing these mutants
as GFP fusion proteins in Ba/F3 cells. Interestingly, deletion of the
SH2 domain resulted in loss of the migration-enhancing properties of
intact Crkl but did not, at least at the levels of expression achieved
in the present studies in Ba/F3 cells, generate a dominant-negative
mutant. In contrast, deletion of the N-terminal, but not the
C-terminal, SH3 domain both resulted in loss of the migration-enhancing
effects of Crkl and reduced spontaneous migration below control levels.
However, the effects of overexpressing Crkl were limited to spontaneous
migration, because after the addition of a strong chemoattractant, the
chemokine SDF-1
, overexpression of Crkl or Crkl mutants had no
additional affects.
SH2 domain after integrin ligation and by
overexpression studies of some of the known proteins that constitutively bind to the Crkl SH3 domains. The major Crkl SH2-binding phosphoprotein was identified as Cbl, a proto-oncogene with multiple YXXP phosphorylation sites that serve as Crkl
SH2-binding
sites (47). v-Cbl is the transforming gene of the Cas NS-1
virus, which causes lymphomas in mice (48). Cbl is the mammalian
homologue of the Sli-1 gene in Caenorhabditis elegans that
is involved in negative regulation of the epidermal growth factor
receptor (49). Targeted disruption of the Cbl locus in mice results in
hyperplasia of T cells, extramedullary hematopoiesis in the spleen, and
ductal hyperplasia of mammary tissue (50). Recent studies suggest that Cbl directs ubiquitination and degradation of ligand-internalized epidermal growth factor receptors in mammalian cells, whereas v-Cbl induces epidermal growth factor receptor recycling to
the surface (51).
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants CA36167 and DK560654 (to J. D. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Dept. of Adult Oncology, Dana-Farber Cancer Inst., 44 Binney St., Boston, MA 02115. Tel.: 617-632-3360; Fax: 617-632-4388.
3 R. Salgia, E. Quackenbush, J. Lin, N. Souchkova, M. Sattler, D. Ewaniuk, K. M. Kulcher, G. Q. Daley, S. K. Kraeft, U. H. von Andrian, L. B. Chen, J.-C. Gutierrez-Ramos, A.-M. Pendergast, and J. D. Griffin, submitted.
2 N. Uemura, R. Salgia, M. Sattler, and J. D. Griffin, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
GFP, green
fluorescent protein;
BSA, bovine serum albumin;
FACS, fluorescence-activated cell sorting;
SDF-1
, stromal-derived
factor-1
;
Ab, antibody.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | ten Hoeve, J., Morris, C., Heisterkamp, N., and Groffen, J. (1993) Oncogene 8, 2469-2474[Medline] [Order article via Infotrieve] |
| 2. |
Arai, A.,
Nosaka, Y.,
Kohsaka, H.,
Miyasaka, N.,
and Miura, O.
(1999)
Blood
93,
3713-3722 |
| 3. |
Barber, D. L.,
Mason, J. M.,
Fukazawa, T.,
Reedquist, K. A.,
Druker, B. J.,
Band, H.,
and D'Andrea, A. D.
(1997)
Blood
89,
3166-3174 |
| 4. |
Boussiotis, V. A.,
Freeman, G. J.,
Berezovskaya, A.,
Barber, D. L.,
and Nadler, L. M.
(1997)
Science
278,
124-128 |
| 5. | Butler, A. A., Yakar, S., Gewolb, I. H., Karas, M., Okubo, Y., and LeRoith, D. (1998) Comp. Biochem. Physiol. 121, 19-26 |
| 6. | Feller, S. M., Posern, G., Voss, J., Kardinal, C., Sakkab, D., Zheng, J., and Knudsen, B. S. (1998) J. Cell. Physiol. 177, 535-552[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Gesbert, F.,
Garbay, C.,
and Bertoglio, J.
(1998)
J. Biol. Chem.
273,
3986-3993 |
| 8. |
Reedquist, K. A.,
Fukazawa, T.,
Panchamoorthy, G.,
Langdon, W. Y.,
Shoelson, S. E.,
Druker, B. J.,
and Band, H.
(1996)
J. Biol. Chem.
271,
8435-8442 |
| 9. |
de Jong, R.,
van Wijk, A.,
Haataja, L.,
Heisterkamp, N.,
and Groffen, J.
(1997)
J. Biol. Chem.
272,
32649-32655 |
| 10. |
Bhat, A.,
Johnson, K. J.,
Oda, T.,
Corbin, A. S.,
and Druker, B. J.
(1998)
J. Biol. Chem.
273,
32360-32368 |
| 11. |
Heaney, C.,
Kolibaba, K.,
Bhat, A.,
Oda, T.,
Ohno, S.,
Fanning, S.,
and Druker, B. J.
(1997)
Blood
89,
297-306 |
| 12. | Kolibaba, K. S., Bhat, A., Heaney, C., Oda, T., and Druker, B. J. (1999) Leuk. Lymphoma 33, 119-126[Medline] [Order article via Infotrieve] |
| 13. |
Nichols, G. L.,
Raines, M. A.,
Vera, J. C.,
Lacomis, L.,
Tempst, P.,
and Golde, D. W.
(1994)
Blood
84,
2912-2918 |
| 14. |
Oda, T.,
Heaney, C.,
Hagopian, J. R.,
Okuda, K.,
Griffin, J. D.,
and Druker, B. J.
(1994)
J. Biol. Chem.
269,
22925-22928 |
| 15. |
Salgia, R.,
Uemura, N.,
Okuda, K.,
Li, J. L.,
Pisick, E.,
Sattler, M.,
de Jong, R.,
Druker, B.,
Heisterkamp, N.,
Chen, L. B.,
and Griffin, J. D.
(1995)
J. Biol. Chem.
270,
29145-29150 |
| 16. |
ten Hoeve, J.,
Arlinghaus, R. B.,
Guo, J. Q.,
Heisterkamp, N.,
and Groffen, J.
(1994)
Blood
84,
1731-1736 |
| 17. | Uemura, N., Salgia, R., Li, J. L., Pisick, E., Sattler, M., and Griffin, J. D. (1997) Leukemia (Baltimore) 11, 376-385[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Astier, A., Manie, S. N., Law, S. F., Canty, T., Haghayghi, N., Druker, B. J., Salgia, R., Golemis, E. A., and Freedman, A. S. (1997) Leuk. & Lymphoma 28, 65-72[Medline] [Order article via Infotrieve] |
| 19. | Feller, S. M., Knudsen, B., and Hanafusa, H. (1995) Oncogene 10, 1465-1473[Medline] [Order article via Infotrieve] |
| 20. |
Kyono, W. T.,
de Jong, R.,
Park, R. K.,
Liu, Y.,
Heisterkamp, N.,
Groffen, J.,
and Durden, D. L.
(1998)
J. Immunol.
161,
5555-5563 |
| 21. |
Koval, A. P.,
Karas, M.,
Zick, Y.,
and LeRoith, D.
(1998)
J. Biol. Chem.
273,
14780-14787 |
| 22. |
Ling, P.,
Yao, Z.,
Meyer, C. F.,
Wang, X. S.,
Oehrl, W.,
Feller, S. M.,
and Tan, T. H.
(1999)
Mol. Cell. Biol.
19,
1359-1368 |
| 23. |
Manie, S. N.,
Beck, A. R. P.,
Astier, A.,
Law, S. F.,
Canty, T.,
Hirai, H.,
Druker, B. J.,
Avraham, H.,
Haghayeghi, N.,
Sattler, M.,
Salgia, R.,
Griffin, J. D.,
Golemis, E. A.,
and Freedman, A. S.
(1997)
J. Biol. Chem.
272,
4230-4236 |
| 24. | Ota, J., Kimura, F., Sato, K., Wakimoto, N., Nakamura, Y., Nagata, N., Suzu, S., Yamada, M., Shimamura, S., and Motoyoshi, K. (1998) Biochem. Biophys. Res. Commun. 252, 779-786[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Sattler, M., Salgia, R., Okuda, K., Uemura, N., Durstin, M. A., Pisick, E., Xu, G., Li, J. L., Prasad, K. V., and Griffin, J. D. (1996) Oncogene 12, 839-846[Medline] [Order article via Infotrieve] |
| 26. |
Salgia, R.,
Pisick, E.,
Sattler, M.,
Li, J.-L.,
Uemura, N.,
Wong, W.-K.,
Burky, S. A.,
Hirai, H.,
Chen, L. B.,
and Griffin, J. D.
(1996)
J. Biol. Chem.
271,
25198-25203 |
| 27. |
Sattler, M.,
Salgia, R.,
Shrikhande, G.,
Verma, S.,
Uemura, N.,
Law, S. F.,
Golemis, E. A.,
and Griffin, J. D.
(1997)
J. Biol. Chem.
272,
14320-14326 |
| 28. |
ten Hoeve, J.,
Kaartinen, V.,
Fioretos, T.,
Haataja, L.,
Voncken, J. W.,
Heisterkamp, N.,
and Groffen, J.
(1994)
Cancer Res.
54,
2563-2567 |
| 29. | Uemura, N., Salgia, R., Ewaniuk, D. S., Little, M. T., and Griffin, J. D. (1999) Oncogene 18, 3343-3353[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Gotoh, A., Takahira, H., Geahlen, R. L., and Broxmeyer, H. E. (1997) Cell Growth Differ. 8, 721-729[Abstract] |
| 31. |
Aiuti, A.,
Webb, I. J.,
Bleul, C.,
Springer, T.,
and Gutierrez-Ramos, J. C.
(1997)
J. Exp. Med.
185,
111-120 |
| 32. |
Posern, G.,
Weber, C. K.,
Rapp, U. R.,
and Feller, S. M.
(1998)
J. Biol. Chem.
273,
24297-24300 |
| 33. |
Ware, M. D.,
Rosten, P.,
Damen, J. E.,
Liu, L.,
Humphries, R. K.,
and Krystal, G.
(1996)
Blood
88,
2833-2840 |
| 34. | Sattler, M., Salgia, R., Shrikhande, G., Verma, S., Choi, J. L., Rohrschneider, L. R., and Griffin, J. D. (1997) Oncogene 15, 2379-2384[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | de Jong, R., van Wijk, A., Heisterkamp, N., and Groffen, J. (1998) Oncogene 17, 2805-2810[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Ichiba, T.,
Kuraishi, Y.,
Sakai, O.,
Nagata, S.,
Groffen, J.,
Kurata, T.,
Hattori, S.,
and Matsuda, M.
(1997)
J. Biol. Chem.
272,
22215-22220 |
| 37. | Posern, G., Zheng, J., Knudsen, B. S., Kardinal, C., Muller, K. B., Voss, J., Shishido, T., Cowburn, D., Cheng, G., Wang, B., Kruh, G. D., Burrell, S. K., Jacobson, C. A., Lenz, D. M., Zamborelli, T. J., Adermann, K., Hanafusa, H., and Feller, S. M. (1998) Oncogene 16, 1903-1912[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Gotoh, T., Hattori, S., Nakamura, S., Kitayama, H., Noda, M., Takai, Y., Kaibuchi, K., Matsui, H., Hatase, O., and Takahashi, H. (1995) Mol. Cell. Biol. 15, 6746-6753[Abstract] |
| 39. |
Lewis, J. M.,
Baskaran, R.,
Taagepera, S.,
Schwartz, M. A.,
and Wang, J. Y.
(1996)
Proc. Natl. Acad. Sci. U. S. A
93,
15174-15179 |
| 40. |
Kiyokawa, E.,
Hashimoto, Y.,
Kurata, T.,
Sugimura, H.,
and Matsuda, M.
(1998)
J. Biol. Chem.
273,
24479-24484 |
| 41. |
Kiyokawa, E.,
Hashimoto, Y.,
Kobayashi, S.,
Sugimura, H.,
Kurata, T.,
and Matsuda, M.
(1998)
Genes Dev.
12,
3331-3336 |
| 42. | Lauffenburger, D. A., and Horwitz, A. F. (1996) Cell 84, 359-369[CrossRef][Medline] [Order article via Infotrieve] |
| 43. |
Polte, T. R.,
and Hanks, S. K.
(1995)
Proc. Natl. Acad. Sci. U. S. A
92,
10678-10682 |
| 44. |
Klemke, R. L.,
Leng, J.,
Molander, R.,
Brooks, P. C.,
Vuori, K.,
and Cheresh, D. A.
(1998)
J. Cell Biol.
140,
961-972 |
| 45. |
Senechal, K.,
Heaney, C.,
Druker, B.,
and Sawyers, C. L.
(1998)
Mol. Cell. Biol.
18,
5082-5090 |
| 46. |
Senechal, K.,
Halpern, J.,
and Sawyers, C. L.
(1996)
J. Biol. Chem.
271,
23255-23261 |
| 47. | Andoniou, C. E., Thien, C. B., and Langdon, W. Y. (1996) Oncogene 12, 1981-1989[Medline] [Order article via Infotrieve] |
| 48. |
Langdon, W. Y.,
Hartley, J. W.,
Klinken, S. P.,
Ruscetti, S. K.,
and Morse, H. C.
(1989)
Proc. Natl. Acad. Sci. U. S. A
86,
1168-1172 |
| 49. |
Yoon, C. H.,
Lee, J.,
Jongeward, G. D.,
and Sternberg, P. W.
(1995)
Science
269,
1102-1105 |
| 50. |
Murphy, M. A.,
Schnall, R. G.,
Venter, D. J.,
Barnett, L.,
Bertoncello, I.,
Thien, C. B.,
Langdon, W. Y.,
and Bowtell, D. D.
(1998)
Mol. Cell. Biol.
18,
4872-4882 |
| 51. |
Levkowitz, G.,
Waterman, H.,
Zamir, E.,
Kam, Z.,
Oved, S.,
Langdon, W. Y.,
Beguinot, L.,
Geiger, B.,
and Yarden, Y.
(1998)
Genes Dev.
12,
3663-3674 |
| 52. | Ojaniemi, M., Langdon, W. Y., and Vuori, K. (1998) Oncogene 16, 3159-3167[CrossRef][Medline] [Order article via Infotrieve] |
| 53. | Robertson, H., Langdon, W. Y., Thien, C. B., and Bowtell, D. D. (1997) Biochem. Biophys. Res. Commun. 240, 46-50[CrossRef][Medline] [Order article via Infotrieve] |
| 54. |
Ojaniemi, M.,
Martin, S. S.,
Dolfi, F.,
Olefsky, J. M.,
and Vuori, K.
(1997)
J. Biol. Chem.
272,
3780-3787 |
| 55. |
Liu, Y.,
Liu, Y. C.,
Meller, N.,
Giampa, L.,
Elly, C.,
Doyle, M.,
and Altman, A.
(1999)
J. Immunol.
162,
7095-7101 |
| 56. |
Dolfi, F.,
Garcia-Guzman, M.,
Ojaniemi, M.,
Nakamura, H.,
Matsuda, M.,
and Vuori, K.
(1998)
Proc. Natl. Acad. Sci. U. S. A
95,
15394-15399 |
| 57. | Wu, Y. C., and Horvitz, H. R. (1998) Nature 392, 501-504[CrossRef][Medline] [Order article via Infotrieve] |
| 58. |
Altun-Gultekin, Z. F.,
Chandriani, S.,
Bougeret, C.,
Ishizaki, T.,
Narumiya, S.,
de Graaf, P.,
Van Bergen en Henegouwen, P.,
Hanafusa, H.,
Wagner, J. A.,
and Birge, R. B.
(1998)
Mol. Cell. Biol.
18,
3044-3058 |
| 59. | Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y., and Noda, M. (1989) Cell 56, 77-84[CrossRef][Medline] [Order article via Infotrieve] |
| 60. |
Kirsch, K. H.,
Georgescu, M. M.,
and Hanafusa, H.
(1998)
J. Biol. Chem.
273,
25673-25679 |
This article has been cited by other articles:
![]() |
P. J. S. Stork and T. J. Dillon Multiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functions Blood, November 1, 2005; 106(9): 2952 - 2961. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Rodrigues, K. E. Fathers, G. Chan, D. Zuo, F. Halwani, S. Meterissian, and M. Park CrkI and CrkII Function as Key Signaling Integrators for Migration and Invasion of Cancer Cells Mol. Cancer Res., April 1, 2005; 3(4): 183 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Valles, M. Beuvin, and B. Boyer Activation of Rac1 by Paxillin-Crk-DOCK180 Signaling Complex Is Antagonized by Rap1 in Migrating NBT-II Cells J. Biol. Chem., October 22, 2004; 279(43): 44490 - 44496. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sanui, A. Inayoshi, M. Noda, E. Iwata, J. V. Stein, T. Sasazuki, and Y. Fukui DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1 Blood, October 15, 2003; 102(8): 2948 - 2950. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lamorte, S. Rodrigues, V. Sangwan, C. E. Turner, and M. Park Crk Associates with a Multimolecular Paxillin/GIT2/{beta}-PIX Complex and Promotes Rac-dependent Relocalization of Paxillin to Focal Contacts Mol. Biol. Cell, July 1, 2003; 14(7): 2818 - 2831. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Voss, P. Gruss, and T. Thomas The guanine nucleotide exchange factor C3G is necessary for the formation of focal adhesions and vascular maturation Development, March 2, 2003; 130(2): 355 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nishihara, M. Maeda, A. Oda, M. Tsuda, H. Sawa, K. Nagashima, and S. Tanaka DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines Blood, December 1, 2002; 100(12): 3968 - 3974. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lamorte, S. Rodrigues, M. Naujokas, and M. Park Crk Synergizes with Epidermal Growth Factor for Epithelial Invasion and Morphogenesis and Is Required for the Met Morphogenic Program J. Biol. Chem., September 27, 2002; 277(40): 37904 - 37911. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. K. Goh, T. Zhu, W.-Y. Leong, and P. E. Lobie c-Cbl Is a Negative Regulator of GH-Stimulated STAT5-Mediated Transcription Endocrinology, September 1, 2002; 143(9): 3590 - 3603. [Abstract] [Full Text] [PDF] |